亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial

医学 维多利祖马布 溃疡性结肠炎 安慰剂 内科学 维持疗法 临床终点 养生 临床试验 胃肠病学 外科 化疗 疾病 病理 替代医学
作者
Brian G. Feagan,Silvio Danese,Edward V. Loftus,Séverine Vermeire,Stefan Schreiber,Timothy E. Ritter,Ronald Fogel,Rajiv M Mehta,Sandeep Nijhawan,Radosław Kempiński,Rafał Filip,Ihor Hospodarskyy,Ursula Elisabeth Seidler,Frank Seibold,Ian Beales,Hyo Jong Kim,John J. Mcnally,Chohee Yun,Sally Zhao,Xiaopeng Liu
出处
期刊:The Lancet [Elsevier BV]
卷期号:397 (10292): 2372-2384 被引量:495
标识
DOI:10.1016/s0140-6736(21)00666-8
摘要

The global prevalence of ulcerative colitis is increasing, and induction and maintenance of remission is a crucial therapeutic goal. We assessed the efficacy and safety of filgotinib, a once-daily, oral Janus kinase 1 preferential inhibitor, for treatment of ulcerative colitis.This phase 2b/3, double-blind, randomised, placebo-controlled trial including two induction studies and one maintenance study was done in 341 study centres in 40 countries. Eligible patients were aged 18-75 years with moderately to severely active ulcerative colitis for at least 6 months before enrolment (induction study A: inadequate clinical response, loss of response to or intolerance to corticosteroids or immunosuppressants, naive to tumour necrosis factor [TNF] antagonists and vedolizumab [biologic-naive]; induction study B: inadequate clinical response, loss of response to or intolerance to any TNF antagonist or vedolizumab, no TNF antagonist or vedolizumab use within 8 weeks before screening [biologic-experienced]). Patients were randomly assigned 2:2:1 to receive oral filgotinib 200 mg, filgotinib 100 mg, or placebo once per day for 11 weeks. Patients who had either clinical remission or a Mayo Clinic Score response at week 10 in either induction study entered the maintenance study. Patients who received induction filgotinib were rerandomised 2:1 to continue their induction filgotinib regimen or to placebo. Patients who received induction placebo continued receiving placebo. The primary endpoint was clinical remission by Mayo endoscopic, rectal bleeding, and stool frequency subscores at weeks 10 and 58. For the induction studies, efficacy was assessed in all randomised patients who received at least one dose of study drug or placebo within that study. For the maintenance study, efficacy was assessed in all patients randomised to any filgotinib treatment group in the induction studies who received at least one dose of study drug or placebo in the maintenance study. Patients who received placebo throughout the induction and maintenance study were not included in the full analysis set for the maintenance study. Safety was assessed in all patients who received at least one dose of the study drug or placebo within each study. This trial is registered with ClinicalTrials.gov, NCT02914522.Between Nov 14, 2016, and March 31, 2020, we screened 2040 patients for eligibility. 659 patients enrolled in induction study A were randomly assigned to receive filgotinib 100 mg (n=277), filgotinib 200 mg (n=245), or placebo (n=137). 689 patients enrolled into induction study B were randomly assigned to receive filgotinib 100 mg (n=285), filgotinib 200 mg (n=262), or placebo (n=142). 34 patients in induction study A and 54 patients in induction study B discontinued the study drug before week 10. After efficacy assessment at week 10, 664 patients entered the maintenance study (391 from induction study A, 273 from induction study B). 93 patients continued to receive placebo. 270 patients who had received filgotinib 100 mg in the induction study were randomly assigned to receive filgotinib 100 mg (n=179) or placebo (n=91). 301 patients who had received filgotinib 200 mg in the induction study were randomly assigned to receive filgotinib 200 mg (n=202) or placebo (n=99). 263 patients discontinued treatment in the maintenance study. At week 10, a greater proportion of patients given filgotinib 200 mg had clinical remission than those given placebo (induction study A 26·1% vs 15·3%, difference 10·8%; 95% CI 2·1-19·5, p=0·0157; induction study B 11·5% vs 4·2%, 7·2%; 1·6-12·8, p=0·0103). At week 58, 37·2% of patients given filgotinib 200 mg had clinical remission versus 11·2% in the respective placebo group (difference 26·0%, 95% CI 16·0-35·9; p<0·0001). Clinical remission was not significantly different between filgotinib 100 mg and placebo at week 10, but was significant by week 58 (23·8% vs 13·5%, 10·4%; 0·0-20·7, p=0·0420). The incidence of serious adverse events and adverse events of interest was similar between treatment groups. In the induction studies, serious adverse events occurred in 28 (5·0%) of 562 patients given filgotinib 100 mg, 22 (4·3%) of 507 patients given filgotinib 200 mg, and 13 (4·7%) of 279 patients given placebo. In the maintenance study, serious adverse events were reported in eight (4·5%) of 179 patients given filgotinib 100 mg, seven (7·7%) of 91 patients in the respective placebo group, nine (4·5%) of 202 patients in the filgotinib 200 mg group, and no patients in the respective placebo group. No deaths were reported during either induction study. Two patients died during the maintenance study; neither was related to treatment.Filgotinib 200 mg was well tolerated, and efficacious in inducing and maintaining clinical remission compared with placebo in patients with moderately to severely active ulcerative colitis.Gilead Sciences.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Shicheng完成签到,获得积分10
1秒前
zhiwei完成签到,获得积分10
2秒前
4秒前
5秒前
11秒前
18秒前
23秒前
腼腆的乘云完成签到,获得积分10
23秒前
Ttimer发布了新的文献求助10
31秒前
自觉康乃馨完成签到,获得积分10
36秒前
ZYP完成签到,获得积分10
43秒前
受伤若男完成签到,获得积分10
1分钟前
1分钟前
拉长的映波完成签到,获得积分10
1分钟前
yoshi发布了新的文献求助10
1分钟前
1分钟前
yoshi完成签到,获得积分10
1分钟前
搜集达人的应助被yoshi采纳,获得10
1分钟前
1分钟前
公冶愚志完成签到 ,获得积分10
2分钟前
2分钟前
失眠晟睿完成签到,获得积分10
2分钟前
平淡的忆梅完成签到,获得积分10
2分钟前
NexusExplorer的应助被飘飘采纳,获得10
2分钟前
烟花的应助被123采纳,获得10
2分钟前
笑点低听枫完成签到,获得积分10
2分钟前
2分钟前
奋斗的石头完成签到 ,获得积分10
2分钟前
机智的觅海完成签到,获得积分10
2分钟前
3分钟前
害羞的乘云完成签到,获得积分10
3分钟前
NeoAir完成签到 ,获得积分10
3分钟前
3分钟前
3分钟前
我很好完成签到 ,获得积分10
3分钟前
3分钟前
3分钟前
3分钟前
现代的初之完成签到,获得积分10
3分钟前
合适雨完成签到,获得积分10
3分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8179896
求助须知:如何正确求助?哪些是违规求助? 9570103
关于积分的说明 21808343
捐赠科研通 7775692
什么是DOI,文献DOI怎么找? 3433193
关于科研通互助平台的介绍 2557334
邀请新用户注册赠送积分活动 2478881